Related Experiment Video
Updated: Jun 13, 2025
14:56
An Experimental Paradigm for the Prediction of Post-Operative Pain PPOP
Published on: January 27, 2010
21.4K
Clinical Characteristics of the Controlled-Release Dinoprostone Vaginal Delivery System (PROPESS)
Mizuki Yamaguchi1, Sho Takakura1, Hiroaki Tanaka1
1Department of Obstetrics and Gynecology, Mie University School of Medicine.
The Tohoku Journal of Experimental Medicine
|September 11, 2024
Summary
The controlled-release dinoprostone vaginal delivery system (PROPESS) requires close monitoring within 4 hours of administration for safe labor induction. This study analyzed PROPESS use in Japan, identifying key characteristics and precautions for effective cervical ripening.
Area of Science:
- Obstetrics and Gynecology
- Reproductive Medicine
- Clinical Pharmacology
Background:
- Cervical ripening is crucial for successful labor induction.
- Effective cervical ripening methods are limited in Japan.
- The controlled-release dinoprostone vaginal delivery system (PROPESS) was approved in Japan in 2020 but lacks widespread adoption.
Purpose of the Study:
- To analyze the clinical characteristics and necessary precautions of PROPESS for cervical ripening.
- To evaluate PROPESS usage in Japanese hospitals.
Main Methods:
- Retrospective observational study of 123 pregnant women administered PROPESS for cervical ripening.
- Data collected from five hospitals in Mie Prefecture, Japan (April 2020 - September 2021).
Main Results:
- The most frequent reason for PROPESS removal was painful uterine contractions (48.5% within 4 hours).
- Non-reassuring fetal status led to removal in 9.8% of cases, often associated with uterine hyperstimulation (50.0% within 4 hours).
- Time to vaginal delivery varied: 28-32 hours for primiparas and 4-8 hours for multiparas.
Conclusions:
- Strict monitoring within the first 4 hours of PROPESS administration is essential for patient safety.
- Findings offer valuable insights for Japanese facilities considering PROPESS implementation.
Related Concept Videos
01:21Drugs for Treatment of Constipation-Predominant IBS
145
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
145
01:29Local Anesthetics: Clinical Application as Epidural Anesthesia
422
Epidural anesthetics are administered in the fat-filled epidural space, the outermost part of the spinal canal. This technique is commonly employed for pain management and anesthesia during lower abdomen and pelvis surgeries or labor and delivery.
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
422
01:17Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
01:29Drug Delivery: Parenteral Route
445
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
445
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
181
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
181
01:18Drug Delivery: Enteral Route
394
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
394